+

WO1998013330A1 - Esters of unsaturated fatty acids - Google Patents

Esters of unsaturated fatty acids Download PDF

Info

Publication number
WO1998013330A1
WO1998013330A1 PCT/GB1997/002502 GB9702502W WO9813330A1 WO 1998013330 A1 WO1998013330 A1 WO 1998013330A1 GB 9702502 W GB9702502 W GB 9702502W WO 9813330 A1 WO9813330 A1 WO 9813330A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
fatty acid
ester
fatty acids
preparation
Prior art date
Application number
PCT/GB1997/002502
Other languages
French (fr)
Inventor
David Frederick Horrobin
Mehar Singh Manku
Austin Mcmordie
Original Assignee
Scotia Holdings Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc
Priority to AU42159/97A priority Critical patent/AU4215997A/en
Publication of WO1998013330A1 publication Critical patent/WO1998013330A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds

Definitions

  • the invention relates to esters of unsaturated fatty acids. Glvcerides
  • fatty acids play many important roles as components of membrane structure, as factors in cell signalling systems and as regulators of gene function.
  • the fatty acids are usually taken in the diet in the form of triglycerides, phospholipids and cholesterol esters.
  • the triglycerides are particularly important vehicles for fatty acids.
  • During the process of digestion the fatty acids at the 1 and 3 positions of the triglyceride are split off by pancreatic lipase, leaving a monoacylglycerol with the fatty acid in the 2 position.
  • This monoacylglycerol may be reconverted by acylation to a diglyceride or triglyceride. or the fatty acid may migrate spontaneously to the 1 or 3 positions. Such migration may possibly be enzyme assisted but may also occur non-enzymically since it can occur in vitro in the absence of enzymes.
  • the 2-monoacylglycerides are important vehicles for the absorption of fatty acids in the small intestine and may be particularly important vehicles for transferring fatty acids into lymphatics which can then take their contents to the blood stream while by-passing the liver.
  • the 2-monoacylglycerides may also have specific biological activities of their own in membranes and in cell signalling systems although as yet these activities are ill-defined.
  • Glycerol has hydroxyl groups in conventionally numbered 1, 2 and 3 positions to which fatty acids may become attached. If the 2-position is occupied by a fatty acid, that fatty acid may migrate to the 1 or 3 positions, thus changing the properties of the monoester, or other fatty acids may be added to the 1 and 3 positions.
  • 2-propanol is related in structure to glycerol, but has no hydroxyl groups at the 1 and 3 positions.
  • the isopropyl esters of fatty acids are therefore analogous to the monoglycerides with the fatty acid in the two position. However such isopropyl esters cannot be converted to di and tri-glycerides, nor can their structure be changed by internal migration of the fatty acid to the 1 or 3 positions.
  • the isopropyl esters therefore provide novel vehicles for the carriage of fatty acids in biological systems and in particular for their unchanged absorption via the lymphatic system.
  • the isopropyl esters may be used as delivery systems whereby unsaturated fatty acids may be effectively delivered to the body, particularly by oral and topical but also by other routes.
  • the fatty acids delivered topically in this way are particularly effectively transported across the skin.
  • the invention provides the isopropyl esters of fatty acids with 16-26 carbon atoms and two to six double bonds in either the cis or the trans configuration, as such and when for use for example in food, cosmetic and therapeutic applications, all as claimed herein.
  • fatty acids include all cis linoleic acid, conjugated linoleic acid, columbinic acid, parinaric acid and all the essential fatty acids of the n-3 and n-6 series, as shown in Table 1. TABLE 1 n-6 EFAs n-3 EFAs
  • LA Linoleic acid
  • ALA Linolenic acid
  • GLA ⁇ -Linolenic acid
  • SA Stearidonic acid
  • DHA Docosahexaenoic acid
  • the acids which in nature are of the all - cis configuration, are systematically named as derivatives of the corresponding octadecanoic, eicosanoic or docosanoic acids, e.g. z,z octadeca - 9,12 - dienoic acid or z,z,z,z,z,z docosa- 4, 7, 10, 13, 16, 19 - hexaenoic acid, but numerical designations based on the number of carbon atoms, the number of centres of unsaturation and the number of carbon atoms from the end of the chain to where the unsaturation begins, such as, correspondingly, 18:2n-6 or 22:6n-3 are convenient.
  • Initials e.g., EPA and shortened forms of the name e.g. eicosapentaenoic acid are used as trivial names in some of the cases.
  • esters may be used for a variety of purposes, but particularly as pharmaceuticals, as foods, as nutritional supplements, as food additives and as agents to be used in all forms of skin and hair care.
  • they When administered to humans or animals, they may be given in doses of from lmg to lOOg per day, preferably lOmg to 30g per day and very preferably lOOmg to 5g per day.
  • skin care agents or other vehicles When incorporated into foods, skin care agents or other vehicles they may be used in concentrations from 0.01 to 50%) preferably 0.5 to 20%, by weight.
  • They may be formulated in capsules, tablets, emulsions, liquids, creams, ointments, skin patches, pessaries, suppositories or any other vehicle for oral, topical, enteral or parenteral administration known to those skilled in the art.
  • Isopropyl esters of bioactive fatty acids may be prepared by any reasonable method of ester synthesis and especially:
  • z,z,z-octadeca-6, 9, 12-trienoic acid 5g, 17.96mmol
  • concentrated sulphuric acid 0.5ml
  • 2-propanol 50ml
  • the mixture was diluted with hexane (25ml) and neutralised with saturated sodium hydrogen carbonate solution.
  • the organic phase was washed with water (2X12ml). dried with magnesium sulphate, filtered, concentrated under reduced pressure and purified by column chromatography to yield z,z,z-octadeca-6, 9, 12-trienoic acid, isopropyl e.ster as a pale yellow oil.
  • z,z,z,z,z,z-eicosa-5, 8, 11,14, 17-pentaenoyl chloride 5g, 15.58mmol
  • 2-propanol 50ml
  • the mixture was concentrated under reduced pressure and purified by column chromatography to yield z,z,z,z,z-eicosa-5, 8, 1 1, 14, 17-pentaenoic acid, isopropyl ester as a yellow oil.
  • Part 2 z,z,z,z,z-eicosa-5, 8, 1 1, 14, 17-pentaenoic acid, isopropyl ester (ester of EPA and isopropanol)
  • Cesium z,z,z,z,z-eicosa-5, 8, 1 1,14, 17-pentaenoate (7.18g 16.53 mmol) and 2-iodopropane (5.62g, 33.06mmol) were heated to 50°C in tetrahydrofuran (55ml) and 1 , 3-dimethyl-3, 4, 5, 6-tetrahydro-2(lH)-pyrimidinone (55ml) with stirring for 3 days under an atmosphere of nitrogen.
  • the mixture was diluted with water (50ml) and a 1 : 1 solution of ethyl acetate and hexane (100ml).
  • the aqueous phase was extracted with ethyl acetate/hexane (1 : 1, 2X250ml).
  • the combined organic phases were washed with saturated sodium chloride solution (2X50ml) and water (50ml), dried with magnesium sulphate, filtered, concentrated under reduced pressure and purified by column chromatography to yield z,z,z,z,z-eicosa-5, 8, 1 1, 14, 17-pentaenoic acid, isopropyl ester as a yellow oil.
  • isopropyl esters of the n-6 EFAs other than GLA, of the n-3 EFAs other than EPA, and of conjugated linoleic acid, parinaric acid and columbinic acid are prepared.
  • Capsules hard or soft gelatin, containing 400mg of the isopropyl ester of linoleic acid, alphalinolenic acid, ga ma-linolenic acid, arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid, or any of the other fatty acids specified.
  • Emulsions for oral or intravenous administration containing 10% by weight of the isopropyl ester of a fatty acid as mentioned in Example 8, suitable natural, synthetic and semi-synthetic emulsifiers, such as phospholipids and galactolipids, known to those skilled in the field being used.
  • suitable natural, synthetic and semi-synthetic emulsifiers such as phospholipids and galactolipids, known to those skilled in the field being used.
  • Galactolipid emulsifiers may in particular be those of our PCT patent application SE 97/001 15 (WO 95/20943)
  • Creams or ointments for topical application prepared as per se known to those skilled in the field and containing 1% by weight of the isopropyl ester of a fatty acid as mentioned in Example 8.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The isopropyl esters of fatty acids with 16-26 carbon atoms and two to six double bonds in either the cis or the trans configuration.

Description

ESTERS OF UNSATURATED FATTY ACIDS
Field of the Invention
The invention relates to esters of unsaturated fatty acids. Glvcerides
In the body fatty acids play many important roles as components of membrane structure, as factors in cell signalling systems and as regulators of gene function. The fatty acids are usually taken in the diet in the form of triglycerides, phospholipids and cholesterol esters. The triglycerides are particularly important vehicles for fatty acids. During the process of digestion the fatty acids at the 1 and 3 positions of the triglyceride are split off by pancreatic lipase, leaving a monoacylglycerol with the fatty acid in the 2 position. This monoacylglycerol may be reconverted by acylation to a diglyceride or triglyceride. or the fatty acid may migrate spontaneously to the 1 or 3 positions. Such migration may possibly be enzyme assisted but may also occur non-enzymically since it can occur in vitro in the absence of enzymes.
The 2-monoacylglycerides are important vehicles for the absorption of fatty acids in the small intestine and may be particularly important vehicles for transferring fatty acids into lymphatics which can then take their contents to the blood stream while by-passing the liver. The 2-monoacylglycerides may also have specific biological activities of their own in membranes and in cell signalling systems although as yet these activities are ill-defined.
Present Work
We believe that there is particular value in developing analogues of the 2- monoacylglycerides. which cannot be converted to di or tri-glycerides. Such analogues are effective in delivering the fatty acids to the lymphatic system and therefore into the blood stream without metabolism in the liver, increasing their biological effectiveness. Glycerol has hydroxyl groups in conventionally numbered 1, 2 and 3 positions to which fatty acids may become attached. If the 2-position is occupied by a fatty acid, that fatty acid may migrate to the 1 or 3 positions, thus changing the properties of the monoester, or other fatty acids may be added to the 1 and 3 positions. 2-propanol is related in structure to glycerol, but has no hydroxyl groups at the 1 and 3 positions. The isopropyl esters of fatty acids are therefore analogous to the monoglycerides with the fatty acid in the two position. However such isopropyl esters cannot be converted to di and tri-glycerides, nor can their structure be changed by internal migration of the fatty acid to the 1 or 3 positions. The isopropyl esters therefore provide novel vehicles for the carriage of fatty acids in biological systems and in particular for their unchanged absorption via the lymphatic system.
The isopropyl esters may be used as delivery systems whereby unsaturated fatty acids may be effectively delivered to the body, particularly by oral and topical but also by other routes. The fatty acids delivered topically in this way are particularly effectively transported across the skin.
Statement of Invention
At its broadest the invention provides the isopropyl esters of fatty acids with 16-26 carbon atoms and two to six double bonds in either the cis or the trans configuration, as such and when for use for example in food, cosmetic and therapeutic applications, all as claimed herein.
Particular examples of the fatty acids include all cis linoleic acid, conjugated linoleic acid, columbinic acid, parinaric acid and all the essential fatty acids of the n-3 and n-6 series, as shown in Table 1. TABLE 1 n-6 EFAs n-3 EFAs
18:2n-6 18:3n-3
Linoleic acid (LA) -linolenic acid (ALA)
Φ δ-6-desaturase Φ
18:3n-6 18:4n-3 γ-Linolenic acid (GLA) Stearidonic acid (SA)
Φ elongation Φ
20:3n-6 20:4n-3
Dihomo-γ-linolenic acid Eicosatetraenoic acid
(DGLA)
Φ δ-5-desaturase Φ
20:4n-6 20: 5n-3
Arachidonic acid (AA)
Eicosapentaenoic acid (EPA)
Φ elongation Φ
22:4n-6 22:5n-3
Adrenic acid
Φ δ-4-desaturase Φ
22:5n-6 22-6n-3 Docosahexaenoic acid (DHA)
The acids, which in nature are of the all - cis configuration, are systematically named as derivatives of the corresponding octadecanoic, eicosanoic or docosanoic acids, e.g. z,z octadeca - 9,12 - dienoic acid or z,z,z,z,z,z docosa- 4, 7, 10, 13, 16, 19 - hexaenoic acid, but numerical designations based on the number of carbon atoms, the number of centres of unsaturation and the number of carbon atoms from the end of the chain to where the unsaturation begins, such as, correspondingly, 18:2n-6 or 22:6n-3 are convenient. Initials, e.g., EPA and shortened forms of the name e.g. eicosapentaenoic acid are used as trivial names in some of the cases.
As noted, the esters may be used for a variety of purposes, but particularly as pharmaceuticals, as foods, as nutritional supplements, as food additives and as agents to be used in all forms of skin and hair care. When administered to humans or animals, they may be given in doses of from lmg to lOOg per day, preferably lOmg to 30g per day and very preferably lOOmg to 5g per day. When incorporated into foods, skin care agents or other vehicles they may be used in concentrations from 0.01 to 50%) preferably 0.5 to 20%, by weight. They may be formulated in capsules, tablets, emulsions, liquids, creams, ointments, skin patches, pessaries, suppositories or any other vehicle for oral, topical, enteral or parenteral administration known to those skilled in the art.
Isopropyl esters of bioactive fatty acids may be prepared by any reasonable method of ester synthesis and especially:
(a) by reaction of 2-propanol with fatty acid chloride, fatty acid anhydride or suitably activated ester with or without the presence of an organic tertiary base, e.g. pyridine, in a suitable inert solvent, e.g., dichloromethane, at a temperature between -40°C and 120°.
(b) by reaction of fatty acid with an excess of 2-propanol in the presence of a suitable acid catalyst, e.g. concentrated sulphuric acid, with or without an inert cosolvent,
e.g. toluene, under reflux conditions.
(c) by reaction of 2-propanol with fatty acid in the presence of a condensing agent, e.g. 1,3-dicyclohexylcarbodiimide, with or without the presence of a suitable organic tertiary base, e.g. 4(N,N-dimethylaminopyridine), in an inert solvent, e.g. dichloromethane, at a temperature between 0° and 50°C.
(d) by reaction of fatty acid or fatty acid activated ester, e.g. vinyl, with an excess of 2-propanol in the presence of a hydrolase enzyme, with or without an inert cosolvent. e.g. hexane, at a temperature between 20°C and reflux. (e) by reaction of fatty acid with suitable 2-propanol derivative, .e.g. iodide, with or without the presence of a suitable base, e.g. potassium carbonate, in a suitable inert solvent, e.g. dimethylformamide, at a temperature between 0° and 180°C.
The following illustrate particular syntheses of the esters.
EXAMPLE 1 z,z,z-octadeca-6, 9, 12-trienoic acid, isopropyl ester (ester of GLA and isopropanol)
A solution of 4-(N,N-dimethylamino)pyridine (2.85g, 23.34mmol) and 1,3- dicyclohexylcarbodiimide (4.08g, 19.75mmol) in methylene chloride (15ml) was added to a stirred solution of z,z,z-octadeca-6, 9, 12-trienoic acid (5g, 17.96 mmol) and 2-propanol (1.19g, 19.75 mmol) in methylene chloride (10ml) at room temperature under an atmosphere of nitrogen. On completion of the reaction as shown by tic, the mixture was filtered, concentrated under reduced pressure and purified by column chromatography to yield z,z,z- octadeca-6, 9, 12-trienoic acid, isopropyl ester as a pale yellow oil.
EXAMPLE 2 z,z,z-octadeca-6, 9, 12-trienoic acid, isopropyl ester (ester of GLA and isopropanol)
z,z,z-octadeca-6, 9, 12-trienoic acid (5g, 17.96mmol), concentrated sulphuric acid (0.5ml) and 2-propanol (50ml) were heated with stirring under reflux. On completion of the reaction as shown by tic, the mixture was diluted with hexane (25ml) and neutralised with saturated sodium hydrogen carbonate solution. The organic phase was washed with water (2X12ml). dried with magnesium sulphate, filtered, concentrated under reduced pressure and purified by column chromatography to yield z,z,z-octadeca-6, 9, 12-trienoic acid, isopropyl e.ster as a pale yellow oil.
EXAMPLE 3 z,z,z-octadeca-6. 9, 12-trienoic acid, isopropyl ester (ester of GLA and isopropanol)
z,z,z-octadeca-6, 9, 12-trienoic acid (5g, 17.96mmol), cesium fluoride (5.46g, 35.92 mmol) and 2-iodopropane (6.1 lg, 35.92 mmol) were heated to 50°C in N,N-dimethylformamide with stirring for 3 days under an atmosphere of nitrogen. The mixture was diluted with ethyl acetate (250ml) and water (100ml). The organic phase was washed with saturated sodium hydrogen carbonate (100ml) and saturated sodium chloride solution (100ml), dried with magnesium sulphate, filtered, concentrated under reduced pressure and purified by column chromatography to yield z,z,z-octadeca-6, 9, 12-trienoic acid, isopropyl ester as a pale yellow oil.
EXAMPLE 4 z,z,z-octadeca-6, 9, 12-trienoic acid, isopropyl ester (ester of GLA and isopropanol)
z,z,z-octadeca-6, 9, 12-trienoic acid (2g, 7.18mmol). immobilised lipase from Candida antarctica (Novozym-435™ (200mg, 10%w/w) and 2-propanol (40ml) were heated with stirring under reflux. On completion of the reaction as shown by tic, the mixture was filtered, concentrated under reduced pressure and purified by column chromatography to yield z,z,z- octadeca-6, 9, 12-trienoic acid, isopropyl ester as a pale yellow oil. EXAMPLE 5 z,z,z,z,z-eicosa-5, 8, 11, 14, 17-pentaenoic acid, isopropyl ester (ester of EPA and isopropanol)
z,z,z,z,z-eicosa-5, 8, 11,14, 17-pentaenoyl chloride (5g, 15.58mmol) and 2-propanol (50ml) were stirred at room temperature under an atmosphere of nitrogen. On completion of the reaction as shown by tic, the mixture was concentrated under reduced pressure and purified by column chromatography to yield z,z,z,z,z-eicosa-5, 8, 1 1, 14, 17-pentaenoic acid, isopropyl ester as a yellow oil.
EXAMPLE 6 z,z,z,z,z-eicosa-5, 8, 1 1 , 14, 17-pentaenoic acid, isopropyl ester (ester of EPA and isopropanol)
Part 1 : cesium z,z,z,z,z-eicosa-5 ,8, 11, 14, 17-pentaenoate (cesium salt of EPA)
z,z,z,z,z-eicosa-5, 8, 11, 14, 17-pentaenoic acid (5g, 16.53mmol) and cesium carbonate (2.70g, 8.27mmol) were dissolved in methanol (150ml) at room temperature. Methanol was removed under reduced pressure to yield cesium z,z,z,z,z-eicosa-5, 8, 1 1, 14, 17-pentaenoate as a waxy orange solid.
Part 2: z,z,z,z,z-eicosa-5, 8, 1 1, 14, 17-pentaenoic acid, isopropyl ester (ester of EPA and isopropanol) Cesium z,z,z,z,z-eicosa-5, 8, 1 1,14, 17-pentaenoate (7.18g 16.53 mmol) and 2-iodopropane (5.62g, 33.06mmol) were heated to 50°C in tetrahydrofuran (55ml) and 1 , 3-dimethyl-3, 4, 5, 6-tetrahydro-2(lH)-pyrimidinone (55ml) with stirring for 3 days under an atmosphere of nitrogen. The mixture was diluted with water (50ml) and a 1 : 1 solution of ethyl acetate and hexane (100ml). The aqueous phase was extracted with ethyl acetate/hexane (1 : 1, 2X250ml). The combined organic phases were washed with saturated sodium chloride solution (2X50ml) and water (50ml), dried with magnesium sulphate, filtered, concentrated under reduced pressure and purified by column chromatography to yield z,z,z,z,z-eicosa-5, 8, 1 1, 14, 17-pentaenoic acid, isopropyl ester as a yellow oil.
EXAMPLE 7
Using the above methods, isopropyl esters of the n-6 EFAs other than GLA, of the n-3 EFAs other than EPA, and of conjugated linoleic acid, parinaric acid and columbinic acid are prepared.
The following are formulation examples for administration for the purposes and in the dosages set out herein.
EXAMPLE 8
Capsules, hard or soft gelatin, containing 400mg of the isopropyl ester of linoleic acid, alphalinolenic acid, ga ma-linolenic acid, arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid, or any of the other fatty acids specified. EXAMPLE 9
Emulsions for oral or intravenous administration containing 10% by weight of the isopropyl ester of a fatty acid as mentioned in Example 8, suitable natural, synthetic and semi-synthetic emulsifiers, such as phospholipids and galactolipids, known to those skilled in the field being used. Galactolipid emulsifiers may in particular be those of our PCT patent application SE 97/001 15 (WO 95/20943)
EXAMPLE 10
Creams or ointments for topical application prepared as per se known to those skilled in the field and containing 1% by weight of the isopropyl ester of a fatty acid as mentioned in Example 8.

Claims

1. The isopropyl esters of fatty acids with 16-26 carbon atoms and two to six double bonds in either the cis or the trans configuration.
2. An ester of an n-6 or n-3 essential fatty acid, conjugated linoleic acid, columbinic acid, or parinaric acid, as in claim 1.
3. A fatty acid ester as in claim 1 or 2, as an acceptable preparation suited to administration of lmg to lOOg preferably lOmg to 30g, very preferably lOOmg to 5g of the fatty acid daily.
4. A fatty acid ester as in claim 1 or 2, as an acceptable preparation for topical application, or as a food, food additive or nutritional supplement, the preparation comprising the fatty acid in the concentration of 0.01 to 50% by weight.
5. When for use in therapy, a fatty acid ester as in claim 1 or 2.
6. When for use in a cosmetic, skin or hair care preparation or in a food, food additive or nutritional supplement, a fatty acid ester as in claim 1 or 2.
7. A method of preparation of a composition for application to the skin in a cosmetic, skin or hair care context or in treatment of dermatological disorders or in delivery of fatty acids to the bloodstream avoiding the hepatic circulation, wherein use is made of an ester as in claim 1 or 2.
PCT/GB1997/002502 1996-09-26 1997-09-17 Esters of unsaturated fatty acids WO1998013330A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU42159/97A AU4215997A (en) 1996-09-26 1997-09-17 Esters of unsaturated fatty acids

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9620248.6A GB9620248D0 (en) 1996-09-26 1996-09-26 Esters of unsaturated fatty acids
GB9620248.6 1996-09-26

Publications (1)

Publication Number Publication Date
WO1998013330A1 true WO1998013330A1 (en) 1998-04-02

Family

ID=10800639

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1997/002502 WO1998013330A1 (en) 1996-09-26 1997-09-17 Esters of unsaturated fatty acids

Country Status (3)

Country Link
AU (1) AU4215997A (en)
GB (1) GB9620248D0 (en)
WO (1) WO1998013330A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1037624A1 (en) * 1997-12-12 2000-09-27 Purdue Research Foundation Methods and compositions for treating diabetes
FR2803749A1 (en) * 2000-01-18 2001-07-20 Pharmascience Lab Inhibition of 5 alpha-reductase activity by fatty esters, useful for prostate hypertrophia and adenoma, acne, hyperseborrhea, alopecia, hirsutism and the like
US6551602B1 (en) * 1999-07-30 2003-04-22 Conopco, Inc. Skin care composition containing conjugated linoleic acid and a phenolic compound
US7015249B1 (en) 1997-12-12 2006-03-21 Purdue Research Foundation Methods and compositions for treating diabetes
FR2940281A1 (en) * 2008-12-22 2010-06-25 Fabre Pierre Dermo Cosmetique ESTER OF DIOL AND POLYUNSATURATED FATTY ACID AS ANTI-ACNE AGENT
US8809560B2 (en) 2011-05-17 2014-08-19 Board Of Trustees Of The University Of Arkansas Trans-, trans-conjugated linoleic acid compositions and use thereof
US9062276B2 (en) 2012-12-03 2015-06-23 Board Of Trustees Of The University Of Arkansas Conjugated linoleic acid rich vegetable oil production from linoleic rich oils by heterogeneous catalysis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05306223A (en) * 1991-07-03 1993-11-19 Takeda Chem Ind Ltd Antifungal topical composition
WO1995000107A1 (en) * 1993-06-22 1995-01-05 Aminco, Inc. Skin and scalp barrier for use with hair treatment products

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05306223A (en) * 1991-07-03 1993-11-19 Takeda Chem Ind Ltd Antifungal topical composition
WO1995000107A1 (en) * 1993-06-22 1995-01-05 Aminco, Inc. Skin and scalp barrier for use with hair treatment products

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ATARASHII GANKA, vol. 12, no. 4, 1995, pages 683 - 688 *
CHEM.ZVESTI, vol. 16, 1962, pages 82 - 88 *
CHEMICAL ABSTRACTS, vol. 121, no. 23, 5 December 1994, Columbus, Ohio, US; abstract no. 271293n, PINTO JULIA C. ET AL.: "Cannabinoid receptor binding and agonist activity of amides and esters of arachidonic acid" page 33; column right; XP002047561 *
CHEMICAL ABSTRACTS, vol. 123, no. 5, 31 July 1995, Columbus, Ohio, US; abstract no. 47841y, SAKAI HIROYUKI ET AL.: "Effect of topical docosahexaenoic acid (DHA) isopropyl ester on retinal function in vitamin E-deficient rabbits" page 79; column left; XP002047560 *
CHEMICAL ABSTRACTS, vol. 59, no. 1, 8 July 1963, Columbus, Ohio, US; abstract no. 433e, STEFAN KOVAC: "The preparation of alkyl esters of cis,cis-delta 9,12-octadecadienoic acid and cis,cis,cis-delta 9,12,15-octadecatrienoic acid." page 263; column 433; XP002047559 *
DATABASE WPI Week 9351, 19 November 1993 Derwent World Patents Index; AN 93-408837, XP002047562 *
MOL.PHARMACOL., vol. 46, no. 3, 1994, pages 516 - 522 *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1037624A1 (en) * 1997-12-12 2000-09-27 Purdue Research Foundation Methods and compositions for treating diabetes
EP1037624A4 (en) * 1997-12-12 2002-05-15 Purdue Research Foundation METHOD AND COMPOSITIONS FOR TREATING DIABETES
US7015249B1 (en) 1997-12-12 2006-03-21 Purdue Research Foundation Methods and compositions for treating diabetes
US6551602B1 (en) * 1999-07-30 2003-04-22 Conopco, Inc. Skin care composition containing conjugated linoleic acid and a phenolic compound
FR2803749A1 (en) * 2000-01-18 2001-07-20 Pharmascience Lab Inhibition of 5 alpha-reductase activity by fatty esters, useful for prostate hypertrophia and adenoma, acne, hyperseborrhea, alopecia, hirsutism and the like
WO2001052837A2 (en) * 2000-01-18 2001-07-26 Laboratoires Pharmascience Use of at least a fatty ester for preparing a composition designed to inhibit 5-$g(a)-reductase activity, in pharmacology, in particular dermatology, in cosmetics and as food additive
WO2001052837A3 (en) * 2000-01-18 2002-06-20 Pharmascience Lab Use of at least a fatty ester for preparing a composition designed to inhibit 5-$g(a)-reductase activity, in pharmacology, in particular dermatology, in cosmetics and as food additive
JP2003520229A (en) * 2000-01-18 2003-07-02 ラボラトワール ファルマシアンス Use of at least one fatty acid ester for the preparation of a composition designed to inhibit 5α-reductase activity in pharmacology, in particular dermatology, in cosmetics and as a food additive.
US8318186B2 (en) 2000-01-18 2012-11-27 Laboratoires Expanscience Use of at least a fatty ester for preparing a composition designed to inhibit 5-α-reductase activity, in pharmacology, in particular dermatology, in cosmetics and as food additive
JP4948732B2 (en) * 2000-01-18 2012-06-06 ラボラトワール エクスパンシアンス Pharmacology, specific dermatology, use in cosmetics and use as a food additive for at least one fatty acid ester to prepare a composition designed to inhibit 5α-reductase activity.
KR20110101152A (en) * 2008-12-22 2011-09-15 삐에르화브르데르모-코스메띠끄 Polyunsaturated Fatty Acid and Diol Ester Anti-acne Formulations
WO2010072738A1 (en) * 2008-12-22 2010-07-01 Pierre Fabre Dermo-Cosmetique Polyunsaturated fatty acid and diol ester as an anti-acne agent
JP2012513380A (en) * 2008-12-22 2012-06-14 ピエール、ファブレ、デルモ‐コスメティーク Polyunsaturated fatty acids and diol esters as anti-acne agents
FR2940281A1 (en) * 2008-12-22 2010-06-25 Fabre Pierre Dermo Cosmetique ESTER OF DIOL AND POLYUNSATURATED FATTY ACID AS ANTI-ACNE AGENT
AU2009331526B2 (en) * 2008-12-22 2013-10-24 Pierre Fabre Dermo-Cosmetique Polyunsaturated fatty acid and diol ester as an anti-acne agent
US8623916B2 (en) 2008-12-22 2014-01-07 Pierre Fabre Dermo-Cosmetique Polyunsaturated fatty acid and diol ester as an anti-acne agent
CN102256930B (en) * 2008-12-22 2014-03-12 皮埃尔·法布尔皮肤化妆品公司 Polyunsaturated fatty acid and diol ester as anti-acne agent
KR101676055B1 (en) 2008-12-22 2016-11-14 삐에르화브르데르모-코스메띠끄 Polyunsaturated fatty acid and diol ester as an anti-acne agent
US8809560B2 (en) 2011-05-17 2014-08-19 Board Of Trustees Of The University Of Arkansas Trans-, trans-conjugated linoleic acid compositions and use thereof
US9062276B2 (en) 2012-12-03 2015-06-23 Board Of Trustees Of The University Of Arkansas Conjugated linoleic acid rich vegetable oil production from linoleic rich oils by heterogeneous catalysis

Also Published As

Publication number Publication date
GB9620248D0 (en) 1996-11-13
AU4215997A (en) 1998-04-17

Similar Documents

Publication Publication Date Title
US5604216A (en) Compositions containing esters of unsaturated fatty acids
US5670540A (en) Triglycerides of fatty acids
USRE43632E1 (en) 1,3-propane diol esters and ethers and methods for their use in drug delivery
US5178873A (en) Essential fatty acid treatment
CA1239587A (en) Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
US4526902A (en) Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
US5328691A (en) Fatty acid compositions
SK14502003A3 (en) Coenzyme Q and eicosapentaenoic acid
US5990164A (en) N-alkylpolyhydroxyamine salts of polyunsaturated fatty acids
WO1998052556A1 (en) Glucosamine fatty acid compositions and their use
EP0823897B1 (en) Nicotinic acid esters and pharmaceutical compositions containing them
WO1998013330A1 (en) Esters of unsaturated fatty acids
GB2311533A (en) Esters of polyunsaturated fatty acids
USRE40546E1 (en) 1,3-Propane diol esters and ethers and methods for their use in drug delivery
WO1998040059A1 (en) Unsaturated fatty acid anhydrides for use in therapy
MXPA97008382A (en) Fatty acid esters as bioacti compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998515363

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载